Evotec to Report First Half 2009 Results On August 7, 2009

* Reuters is not responsible for the content in this press release.

Thu Jul 30, 2009 8:20am EDT 

HAMBURG, Germany, July 30, 2009 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT)
(Nasdaq:EVTC) will report its financial results for the first half of 2009 on
Friday, August 7, 2009.

The Company is going to hold a conference call to discuss the results:

Conference call details:

 Date:        Friday, August 7, 2009
 Time:        09.30 a.m. CEST
              08.30 a.m. BST
              03.30 a.m. US time (East Coast)

 From Europe: +49.(0)69.5007 1308 (Germany)
              +44.(0)20.7806 1956 (UK)
 From the US: +1.718.354 1388
 Access Code: 8676443
A simultaneous slide presentation for participants dialing in via phone is
available at www.equitystory.com, password: evotec0809.

Webcast details

To join the audio webcast and to access the presentation slides, you will find a
link on our home page www.evotec.com shortly before the event.

A replay of the conference call will be available for 24 hours and can be
accessed in Europe by dialing +49.(0)69.22222 0418 (Germany) or +44.(0)20.7806
1970 (UK) and in the US by +1.718.354 1112. The access code is 8676443#. The
on-demand version of the webcast will be available on our website:
www.evotec.com - Investors - Financial Reports.

About Evotec AG

Evotec is a leader in the discovery and development of novel small molecule
drugs. The Company has built substantial drug discovery expertise and an
industrialized platform that can drive new innovative small molecule compounds
into the clinic. In addition, Evotec has built a deep internal knowledge base in
the treatment of diseases related to neuroscience, pain, and inflammation.
Leveraging these skills and expertise, the Company intends to develop
best-in-class differentiated therapeutics and deliver superior science-driven
discovery alliances with pharmaceutical and biotechnology companies. Evotec has
long-term discovery alliances with partners including Boehringer Ingelheim,
CHDI, Novartis, Ono Pharmaceutical and Roche. The Company has a P2X7 antagonist
for the treatment of inflammatory diseases in clinical development and a series
of preclinical compounds and development partnerships, including a strategic
alliance with Roche for EVT 101, a subtype selective NMDA receptor antagonist,
for use in treatment-resistant depression.

-0-
CONTACT:  Evotec AG
          Dr Werner Lanthaler, Chief Executive Officer
          +49.(0)40.56081-242
          werner.lanthaler@evotec.com
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.